Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of … Recruiting

2023-503931-17-00 Geographic Atrophy 2024-03-28
Allopurinol as a preventive drug in patients with high and very high cardiovascular risk, taking into account the presence of the long-COVID… Recruiting

2024-517610-15-00 hyperuricemia, hypertension, ischemic stroke, intracere 2024-03-28
Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenoc… Recruiting

2023-506885-30-00 Adult patients with intermediate low or mid rectal aden 2024-03-26
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 2024-03-25
A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antid… Recruiting

2024-513019-29-00 Major Depression Disorder 2024-03-22
Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroi… Recruiting

2023-504756-96-00 Recurrent pericarditis, idiopathic or secondary to inva 2024-03-22
Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression Recruiting

2024-516022-63-00 Patients with symptomatic and pre-symptomatic Huntingto 2024-03-21
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 2024-03-20
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 2024-03-19
DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dap… Recruiting

2023-508502-18-00 Alport syndrome 2024-03-19
Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting

2023-505267-36-00 Glioblastoma 2024-03-15
A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting

2023-506330-73-00 Advanced (unresectable or metastatic) human epidermal g 2024-03-13
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho… Recruiting

2023-505141-48-00 Fibrosis 2024-03-07
CAPSAPED Recruiting

2022-500265-27-00 Chronic postchirurgical or post-traumatic neuropathic p 2024-03-05
Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2023-504735-41-00 Moderately to Severely Active Crohn's Disease 2024-03-05
RECOVERY Recruiting

2023-507441-29-00 Pneumonia 2024-02-29
A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSM… Recruiting

2022-500570-33-00 Prostate cancer 2024-02-28
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting

2023-505251-43-00 Primary Biliary Cholangitis 2024-02-28
the BIRDIE trial Recruiting

2023-505839-12-01 Severe asthma 2024-02-26
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 2024-02-23
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting

2023-504863-17-00 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic 2024-02-21
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 2024-02-20
Weaning protocol for high-flow nasal oxygen therapy in the ICU - Multicenter randomized controlled trial. HiFloWEAN Recruiting

2023-504366-36-00 de novo acute respiratory failure 2024-02-17
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 2024-02-14